Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B

Amneal Pharmaceuticals, Inc.

Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).
Q4 adjusted net income $71M, adjusted EBITDA $154M (+26% YoY), adjusted diluted EPS $0.23.
Full year 2022 net revenue $2.21B (+6% YoY); GAAP net loss $130M ($0.86 loss per share) including $263M Opana litigation charge.
Full year adjusted EBITDA $514M (+$2M YoY), adjusted diluted EPS $0.68.
2023 guidance: net revenue $2.25-2.35B, adjusted EBITDA $500-530M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $610 million, net income $4 million, EPS $0.03. Guidance initiated.

Period: the fourth quarter ended December 31, 2022
Revenue: $610 million
Net income: $4 million
EPS: $0.03
Guidance: initiated
Result: reported results

Exact text from the filing

Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.21 billion, net income $130 million, EPS $0.86. Guidance initiated.

Period: the year ended December 31, 2022
Revenue: $2.21 billion
Net income: $130 million
EPS: $0.86
Guidance: initiated
Result: reported results

Exact text from the filing

Full Year 2022 Net Revenue of $2.21 billion; GAAP Net Loss of $130 million; Diluted Loss per Share of $0.86

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.